Key result
This review summarizes the pharmacological highlights of new anticoagulants and provides best-practice recommendations for withholding these drugs before endoscopic procedures.
This review provides essential guidance for gastroenterologists on managing patients taking new anticoagulants and antiplatelet agents prior to endoscopic procedures.
Answers are grounded in this paper and cite their sources.
May guide periprocedural withholding of new anticoagulants; leaves open prospective validation of recommendations.
The discovery of the first oral anticoagulant, warfarin, was a milestone in anticoagulation. Warfarin's well-known limitations, however, have led to the recent development of more effective anticoagulants. The rapidly growing list of these drugs, however, presents a challenge to endoscopists who must treat patients on these sundry medications. This review is intended to summarize the pharmacological highlights of new anticoagulants, with particular attention to suggested "best-practice" recommendations for the withholding of these drugs before endoscopic procedures.
No takes yet. Share an insight, caveat, or question.
Parekh et al. (2014) conducted a review in Patients on new anticoagulants undergoing endoscopic procedures. New anticoagulants and antiplatelet agents was evaluated. This review summarizes the pharmacological highlights of new anticoagulants and provides best-practice recommendations for withholding these drugs before endoscopic procedures.
Synapse has enriched 10 related papers. Consider them for comparative context: